Bottarga fish roe in adults with prediabetes, diabetes, or high cholesterol
Tests daily bottarga fish roe in adults with metabolic health problems.
Key facts
- Who runs it
- Cambridge Health Alliance
- Where
- Sommerville, United StatesSee the site
- Trial code
- Registry title
- Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 17 Oct 2025
- Expected to end
- 1 Mar 2027
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Bottarga
- Comparator
- Record updated
- 16 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-60 who live in Massachusetts and have at least one metabolic abnormality or diabetes. They will eat Greek bottarga (grey mullet fish roe) or a dairy product each day.
- Age
- 18 to 60 years
- Sex
- Men and women can join.
- Disease stage
- At least one metabolic abnormality (low HDL cholesterol, high LDL cholesterol, high triglycerides, obesity, or HbA1c ≥ 5.7% (39 mmol/mol)) or a diagnosis of diabetes.
- Earlier treatment
- People cannot be using diabetes medicines (except metformin), cholesterol medicines (except statins), immunosuppressive medicines, hormone therapy (except oral contraceptives), or supplements containing n-3 fatty acids.
- Biomarker or test result
- HbA1c of 5.7% (39 mmol/mol) or higher, or abnormal HDL, LDL or triglyceride levels, count as a metabolic abnormality.
Main reasons for not taking part
- Allergy to fish, seafood or fish-derived products
- Pregnancy
- Liver or kidney insufficiency, now or in the past
- Immunodeficiency conditions
- History of non-skin cancer
The registry criteria, word for word
Show all 15 criteriaShow less
Who cannot take part
- Current use of illicit drugs (other than marijuana)
- Use of hormone therapy (except oral contraceptives)
- Use of any medications for diabetes (except metformin), dyslipidemia (except statins), or immunosuppression
- Known allergies to fish, seafood, or any fish-derived products, including bottarga
- Clinical evidence or history of hepatic or renal insufficiency
- Immunodeficiency conditions
- History of non-skin cancer
- Current use of any supplements containing n-3 fatty acids
- Pregnancy
- Participation in other clinical research studies
Other criteria
- Adults aged 18-60 years
- Residents of Massachusetts
- Presence of at least one metabolic abnormality (low HDL cholesterol, elevated LDL cholesterol, elevated triglycerides, obesity, or HbA1c ≥ 5.7%) or a diagnosis of diabetes
- Not pregnant
- Willing to consume a nutritional supplement and comply with study procedures
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Where in United States
- Cambridge Health AllianceSommerville, United StatesContact: Patricia LenehanTaking people
About the trial
What the trial wants to find out
This pilot study aims to explore the potential benefits of consuming Greek bottarga (grey mullet fish roe) in individuals with at least one metabolic abnormality (low HDL cholesterol, high LDL cholesterol, high triglycerides, obesity, or HbA1c ≥ 5.7%) or a diagnosis of diabetes.
Read full original descriptionShow less
Before initiating the crossover randomized controlled trial (RCT), the investigators will conduct a preliminary dose-testing study in five adults with at least one metabolic abnormality. Participants will undergo clinical assessments before and after the dietary intervention to evaluate changes in metabolic health markers. Following this phase, the investigators will proceed with a randomized, controlled crossover trial involving 20 eligible adult participants. This main study phase will compare the metabolic effects of daily bottarga supplementation with those of a calorically matched dairy product over an 8-week intervention period, with a 2-week washout period between interventions.
The investigators anticipate that bottarga supplementation will improve lipid profiles, inflammation markers, and insulin resistance, thereby supporting the potential use of sustainable blue foods as part of a healthy diet.
The 2 groups in the trial
- Bottarga supplementation (intervention group)Treatment being tested
Ten participants with at least one metabolic abnormality (low HDL cholesterol, high LDL cholesterol, high triglycerides, obesity, or HbA1c ≥ 5.7%) or a diagnosis of diabetes will be randomly allocated to 8 weeks of daily bottarga supplementation (20 grams/day; participants weighing \>100 kg \[220 lbs\] will consume 40 g/day) as an initial treatment. Baseline assessment measures will be repeated, followed by a 2-week wash-out period. Then, assessment measures will be repeated followed by 8 weeks of daily cream cheese supplementation (28 grams/day; participants weighing \>100 kg \[220 lbs\] will consume 56 g/day), followed by final assessment measures.
Treatment: Bottarga
- Cream cheese supplementation (control)Sham treatment, for comparison
Ten participants with at least one metabolic abnormality (low HDL cholesterol, high LDL cholesterol, high triglycerides, obesity, or HbA1c ≥ 5.7%) or a diagnosis of diabetes will be randomly allocated to 8 weeks of daily cream cheese supplementation (28 g/day) as the initial intervention. Baseline assessment measures will be repeated, followed by a 2-week wash-out period. Then, assessment measures will be repeated, followed by 8 weeks of daily Bottarga supplementation (20 g/day;participants weighing \>100 kg \[220 lbs\] will consume 40 g/day), followed by final assessment measures.
Treatment: Comparator
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food
- Plain-language title
- Bottarga fish roe in adults with prediabetes, diabetes, or high cholesterolGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06988462, who can take part
- Record updated
- 16 July 2026